# 2026-16444: NIH Eyes Exclusive License for Cancer Surgery Glow Dye to Maryland Firm

2026-16444, Prospective Grant of an Exclusive Patent License: Development and Commercialization of BL-760 Dye for Intraoperative Fluorescence Imaging, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-08-12, effective Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 27, 2026 will be considered. (as of 2026-08-19).

- Canonical: https://policyrisk.com/federal-register/2026-16444
- As of: 2026-08-19
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-16444
- Title: Prospective Grant of an Exclusive Patent License: Development and Commercialization of BL-760 Dye for Intraoperative Fluorescence Imaging
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 52061
- Published: 2026-08-12
- Effective: Only written comments and/or applications for a license which are received by the National Cancer Institute's Technology Transfer Center on or before August 27, 2026 will be considered.
- Comments close: 2026-08-27
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-08-19

## In one line

NIH Eyes Exclusive License for Cancer Surgery Glow Dye to Maryland Firm

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patents and patent applications listed in the Supplementary Information section of this notice to OptoSurgical LLC ("OptoSurgical"), a company located in Columbia, Maryland, the United States of America.

## Effects PRIA read

No economic effects identified for this document.

## Related documents

- [2026-22871](https://policyrisk.com/federal-register/2026-22871): Center for Scientific Review; Notice of Closed Meetings, 2026-11-10
- [2026-22550](https://policyrisk.com/federal-register/2026-22550): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22558](https://policyrisk.com/federal-register/2026-22558): Center for Scientific Review; Notice of Closed Meetings, 2026-11-05
- [2026-22339](https://policyrisk.com/federal-register/2026-22339): Prospective Grant of Exclusive Patent License: Catheter-Based Intramyocardial Ablation for Treating Ventricular Arrhythmia in a Human, 2026-11-02
- [2026-22196](https://policyrisk.com/federal-register/2026-22196): National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meeting, 2026-10-30
- [2026-22111](https://policyrisk.com/federal-register/2026-22111): Eunice Kennedy Shriver National Institute of Child Health & Human Development; Notice of Meeting, 2026-10-29

## Sources
- [2026-16444 on federalregister.gov](https://www.federalregister.gov/documents/2026/08/12/2026-16444/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-bl-760-dye-for)
- [2026-16444 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-08-12/pdf/2026-16444.pdf)

## Related
- [Previous: 2026-16443, Government Owned Invention Available for License: Monoclonal Antibody (RO4) Tha…](https://policyrisk.com/federal-register/2026-16443)
- [Next: 2026-16445, Agency Information Collection Activities; Submission to the Office of Managemen…](https://policyrisk.com/federal-register/2026-16445)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-16444 (as of 2026-08-19).